Cyclopentolate

Summary

Cyclopentolate (CHEMBL1201338) is an approved small-molecule mydriatic agent (ATC S01FA54); indicated across 2 conditions including myopia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01FA54 (+1 more)
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 291.4 Da · C17H25NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201338
Name	Cyclopentolate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2905
ChEBI	CHEBI:4024
ATC	S01FA54, S01FA04
Molecular formula	C17H25NO3
Molecular weight	291.4
InChIKey	SKYSRIRYMSLOIN-UHFFFAOYSA-N

SMILES: CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O

IUPAC name: 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate

ChEBI definition: A carboxylic ester resulting from the formal condensation of (1-hydroxycyclopentyl)(phenyl)acetic acid with N,N-dimethylethanolamine. A tertiary amine antimuscarinic with actions similar to atropine, it is used as its hydrochloride salt to produce mydriasis (excessive dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) for opthalmic diagnostic procedures. It acts more quickly than atropine and has a shorter duration of action.

Pharmacological roles (ChEBI): mydriatic agent, parasympatholytic, muscarinic antagonist, diagnostic agent.

Also known as: Bell pentolate, Ciclopentolato, Cyclopentolate, cyclopentolate, CYCLOPENTOLATE, CYCLOPENTOLATECYCLOPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1200473

Patent coverage: 1,215 distinct patent families (4,554 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM3	7.4	AC50	40	nM	CHEMBL_ACT_25137035
CHRM1	7.16	AC50	69	nM	CHEMBL_ACT_25135820
CHRM2	6.54	AC50	290	nM	CHEMBL_ACT_25214076
CHRM2	6.21	AC50	623.8	nM	CHEMBL_ACT_25195356

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myopia	1	MONDO:0001384	HP:0000545

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	4
Not specified	3
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02177539	PHASE4	UNKNOWN	A New More Efficient Cycloplegia Scheme
NCT03638726	PHASE4	UNKNOWN	Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
NCT05442801	PHASE4	COMPLETED	Cycloplegic Refraction Among Children
NCT06077682	PHASE4	UNKNOWN	Cycloplegic Refraction in Pediatric Patients With Esotropia
NCT03851172	PHASE2	UNKNOWN	Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery
NCT00348166	PHASE1	WITHDRAWN	Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children?
NCT02909140	Not specified	TERMINATED	Optimal Method for Mydriasis in Cataract Surgery
NCT03375996	Not specified	COMPLETED	Evaluation of a Protocol of Pupil Dilation Before Laser-assisted Cataract Surgery
NCT05614622	Not specified	COMPLETED	Mydriatic Drops After Combined Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).